Shopping Cart 0
Cart Subtotal
USD 0

Neurofibromatoses Type I (Von Recklinghausen Disease)-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Neurofibromatoses Type I (Von Recklinghausen Disease)-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I (Von Recklinghausen Disease)-Pipeline Review, H1 2017, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen Disease) (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 1 (NF1), also called von Recklinghausen disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen Disease)-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Von Recklinghausen Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Neurofibromatoses Type I (Von Recklinghausen Disease) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Von Recklinghausen Disease) (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen Disease) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neurofibromatoses Type I (Von Recklinghausen Disease) (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neurofibromatoses Type I (Von Recklinghausen Disease) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen Disease) (Genetic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen Disease) (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Von Recklinghausen Disease) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neurofibromatoses Type I (Von Recklinghausen Disease)-Overview

Neurofibromatoses Type I (Von Recklinghausen Disease)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neurofibromatoses Type I (Von Recklinghausen Disease)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neurofibromatoses Type I (Von Recklinghausen Disease)-Companies Involved in Therapeutics Development

Alexion Pharmaceuticals Inc

Array BioPharma Inc

AstraZeneca Plc

Celldex Therapeutics Inc

Neurofibromatoses Type I (Von Recklinghausen Disease)-Drug Profiles

asfotase alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

binimetinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-0158-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selumetinib sulfate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurofibromatoses Type I-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neurofibromatoses Type I (Von Recklinghausen Disease)-Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Neurofibromatoses Type I (Von Recklinghausen Disease)-Pipeline by Alexion Pharmaceuticals Inc, H1 2017

Neurofibromatoses Type I (Von Recklinghausen Disease)-Pipeline by Array BioPharma Inc, H1 2017

Neurofibromatoses Type I (Von Recklinghausen Disease)-Pipeline by AstraZeneca Plc, H1 2017

Neurofibromatoses Type I (Von Recklinghausen Disease)-Pipeline by Celldex Therapeutics Inc, H1 2017

Neurofibromatoses Type I (Von Recklinghausen Disease)-Dormant Projects, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Neurofibromatoses Type I (Von Recklinghausen Disease) Therapeutic Products under Development, Key Players in Neurofibromatoses Type I (Von Recklinghausen Disease) Therapeutics, Neurofibromatoses Type I (Von Recklinghausen Disease) Pipeline Overview, Neurofibromatoses Type I (Von Recklinghausen Disease) Pipeline, Neurofibromatoses Type I (Von Recklinghausen Disease) Pipeline Assessment


Companies

Alexion Pharmaceuticals Inc

Array BioPharma Inc

AstraZeneca Plc

Celldex Therapeutics Inc